1HM Stock Overview
A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Adaptive Biotechnologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$7.55 |
| 52 Week Low | US$2.15 |
| Beta | 1.34 |
| 11 Month Change | -4.52% |
| 3 Month Change | 1.21% |
| 1 Year Change | -53.67% |
| 33 Year Change | -91.01% |
| 5 Year Change | n/a |
| Change since IPO | -90.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1HM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -3.9% | 0.09% |
| 1Y | -53.7% | -15.6% | 3.1% |
Return vs Industry: 1HM underperformed the German Life Sciences industry which returned -15.6% over the past year.
Return vs Market: 1HM underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 1HM volatility | |
|---|---|
| 1HM Average Weekly Movement | 12.1% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1HM's share price has been volatile over the past 3 months.
Volatility Over Time: 1HM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 709 | Chad Robins | www.adaptivebiotech.com |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
Adaptive Biotechnologies Corporation Fundamentals Summary
| 1HM fundamental statistics | |
|---|---|
| Market cap | €446.53m |
| Earnings (TTM) | -€201.12m |
| Revenue (TTM) | €163.19m |
2.7x
P/S Ratio-2.2x
P/E RatioIs 1HM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1HM income statement (TTM) | |
|---|---|
| Revenue | US$174.50m |
| Cost of Revenue | US$194.68m |
| Gross Profit | -US$20.18m |
| Other Expenses | US$194.88m |
| Earnings | -US$215.06m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | -11.57% |
| Net Profit Margin | -123.24% |
| Debt/Equity Ratio | 47.9% |
How did 1HM perform over the long term?
See historical performance and comparison